Johnson & Johnson said in a study on non-small cell lung cancer, RYBREVANT combined chemotherapy reduced the risk of death by 43%.

Zhitongcaijing · 2d ago
Johnson & Johnson said in a study on non-small cell lung cancer, RYBREVANT combined chemotherapy reduced the risk of death by 43%.